Research
Emerging Infectious Diseases Vol. 12, No. 5, May 2006
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evi
...
dence-based policies.
more
Research Article
BMC Infectious Diseases 2014, 14:91/1471-2334/14/91
PLOS ONE | DOI:10.1371/journal.pone.0142290 November 9, 2015; 1 / 16
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for is
...
oniazid-resistant TB (Hr-TB) and MDR/RR-TB, including longer and shorter regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care.
more
Review
S Afr Med J 2014;104(3):174-177. DOI: 10.7196/SAMJ.7968
PLOS ONE | DOI:10.1371/journal.pone.0155525 May 19, 2016, 1 / 11
4th edition. This is fourth edition of Treatment of tuberculosis: guidelines, adhering fully to the new WHO process for evidence-based guidelines. Several important recommendations are being promoted in this new edition
Moving avidence into action
This document is part of a series of briefs for health program managers interested in implementing evidence-based programs. With a special emphasis on underutilized interventions, they present evidence on programs that work and provide guidance and resources for replicat
...
ion.
more
HIV/TB Research Meeting; March 3, 2013
PLoSONE 12(9):e0184986.https://doi.org/10.1371/journal.pone.0184986
Профілактичне лікування ізоніазидом. Що це таке?